Survodutide Demonstrates Efficacy in Phase III Trial for Obesity and Type 2 Diabetes

Detailed Phase III SYNCHRONIZE-2 trial results for survodutide (BI 456906) were presented and published. The glucagon/GLP-1 receptor dual agonist achieved up to 13.1% body weight reduction and improved glycemic control in adults with obesity or overweight and type 2 diabetes. These findings suggest its potential to address metabolic drivers and enhance cardiometabolic health.